[Iatrogenic hyperkalemia].

R Krapf

Home/Archive/PubMed

PubMed · 8668977

[Iatrogenic hyperkalemia].

R Krapf

View original source ↗Export metadata ↓

Abstract

Iatrogenic causes are important contributors to hyperkalemia in clinical practice. Most iatrogenic causes are drug-related, involving interference by the drugs with potassium metabolism at the level of renal handling and/or transcellular distribution of potassium. By discussion of the mechanisms of iatrogenic hyperkalemia it is hoped that the incidence of this potentially serious complication can be reduced.

Explore related subjects

Aldosterone Drug-Related Side Effects and Adverse Reactions Humans Hyperkalemia Iatrogenic Disease Kidney Kidney Tubules Renin-Angiotensin System English Abstract Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

R Krapf. 1996-04-13. [Iatrogenic hyperkalemia].. https://pubmed.ncbi.nlm.nih.gov/8668977/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2002

Aldosterone augments endothelin-1-induced cardiac myocyte hypertrophy with the reinforcement of the JNK pathway.

Aldosterone is thought to regulate cardiac work independently of sodium retention, though the mechanisms remain to be known. In the present study, we have demonstrated that aldosterone reinforces endothelin-mediated cardiac hypertrophy with the increase in cell surface area and upregulation of the transcripts characteristic of hypertrophy. We have also shown that aldosterone augments c-Jun N-terminal kinase activation induced by endothelin-1. Taken together, it is suggested that aldosterone modulates cardiac hypertrophy, at least partially, synergistically with extracellular signals that have been shown to be involved in cardiac remodeling.

Aldosterone↗

PubMed2002

The mineralocorticoid receptor in rodent retina: ontogeny and molecular identity.

PURPOSE: Mineralocorticoid hormones contribute to ion-water balance in all cell types. In this study, we investigated the presence of mineralocorticoid receptors in rat and bovine ocular tissues and during retinal development. METHODS: Isolated photoreceptors and/or intact retina, retinal pigment epithelium (RPE) cells, and ciliary body were analyzed for the expression of MR (Mineralocorticoid Receptor) using the polymerase chain reaction (PCR) technique. Since aldosterone can stimulate the expression of epithelial Na+ channels (ENaC), expression of this gene in RPE was measured under basal and aldosterone-induced level. RESULTS: MR was expressed in rat photoreceptors and in the inner retina (inner nuclear layer and ganglion cell layer) even one day after birth, almost hundred percent identity was observed between rat retina and kidney MR gene products. The expression was also present in the RPE and in the ciliary body. ENaC gene was expressed in RPE and generated a predicted band at 520 bp following RT-PCR amplification which was 95% homology to that of ENaC mRNA from bovine kidney. The incubation of RPE cells in vitro with aldosterone increased the mRNA level of ENaC. CONCLUSIONS: MR expression in the mammalian retina, RPE, and ciliary body extends the potential field of action for mineralocorticoid hormones. Results on RPE cells are consistent with the idea that steroid hormones may regulate the physiology of these tissues by modulating ENaC expression. This study provides new light on the potential effect of mineralocorticoid in this area of the nervous system.

Aldosterone↗

PubMed2002

Effects of perindopril on aldosterone production in the failing human heart.

The present study was designed to examine whether the production of aldosterone from the heart is suppressed by angiotensin-converting enzyme (ACE) inhibition in patients with heart failure. Forty-one patients with left ventricular systolic dysfunction were randomly divided into either the perindopril group (n = 21, perindopril 4 mg/day) or the placebo group (n = 20). Plasma levels of aldosterone and ACE activity were measured in the anterior interventricular vein, coronary sinus, and aortic root during cardiac catheterization. The levels of aldosterone as well as ACE activity were significantly higher at the anterior interventricular vein and the coronary sinus than at the aortic root in the placebo group (aldosterone: 92.1 +/- 9.0 vs 70.6 +/- 8.3 pg/ml [p <0.001]; 90.3 +/- 9.2 vs 70.6 +/- 8.3 pg/ml [p <0.001], respectively; ACE activity: 13.6 +/- 0.8 vs 12.2 +/- 0.7 IU/L [p <0.001], 13.4 +/- 0.8 vs 12.2 +/- 0.7 IU/L [p <0.001], respectively). On the other hand, there were no differences in the levels of aldosterone or ACE activity between the anterior interventricular vein and aortic root or between the coronary sinus and aortic root (aldosterone: 68.1 +/- 8.4 vs 69.9 +/- 9.4 pg/ml [p = NS]; 67.3 +/- 8.9 vs 69.9 +/- 9.4 pg/ml [p = NS], respectively; ACE activity: 9.7 +/- 0.8 vs 9.9 +/- 0.8 IU/L [p = NS]; 9.8 +/- 0.8 vs 9.9 +/- 0.8 IU/L, respectively) in the perindopril group. The levels of aldosterone as well as ACE activity were significantly lower at the anterior interventricular vein and coronary sinus in the perindopril group than in the placebo group. The difference in the level of aldosterone between the anterior interventricular vein and aortic root (Delta aldosterone [anterior interventricular vein - aortic root]) had a significant positive correlation with that of ACE activity (Delta ACE [anterior interventricular vein - aortic root]) (r = 0.536, p <0.001), whereas ACE activity in the aortic root had no significant correlation with either the aldosterone levels in the aortic root or Delta aldosterone (anterior interventricular vein - aortic root). Perindopril suppressed cardiac aldosterone production by mainly suppressing cardiac ACE activity in patients with heart failure. Thus, aldosterone production is activated in the failing ventricle and is suppressed by perindopril mainly via the suppression of cardiac ACE activity in patients with heart failure.

Aldosterone↗